Ovid Therapeutics Inc. Common Stock
OVIDOvid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for rare neurological disorders. Founded to address unmet medical needs, the company specializes in leveraging its expertise in neuroscience to bring innovative therapies to patients with conditions such as rare epilepsies and other central nervous system disorders.
Company News
Ovid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.
Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.
The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.
Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that it will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology company focused on developing Rho-associated coiled-coil co...
